Insmed (STU:IM8N) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:IM8N Insmed Inc STU:IM8N
71 GF Score
Price €85.69
GF Value €162.54
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Insmed Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Insmed Valuation Rank Related Terms

STU:IM8N
71GF Score
Insmed Inc STU:IM8N
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Insmed (STU:IM8N) Overvalued in 2026?

Based on GuruFocus' analysis, Insmed stock appears to be undervalued. The current stock price of €85.69 is trading 47.3% below its estimated GF Value™ of €162.54. GuruFocus considers Insmed to be Possible Value Trap.

Key valuation signals for STU:IM8N:

  • Valuation Rank:
  • GF Value™: €162.54 vs. price of €85.69 (47.3% below fair value)
  • GF Score™: 71/100 with 4 warning signs

No single metric tells the full story. See the STU:IM8N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Insmed Business Description

Address 700 US Highway 202/206, Bridgewater, NJ, USA, 08807
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
71GF Score

Get the complete analysis for STU:IM8N

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€85.69
Price
€162.54
GF Value